Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ABBV

Abbvie Inc

Dec 20 • 04:00PM ET

175.58

Dollar change +4.06
Percentage change 2.37	%

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: JNJ PFE MRK LLY BMY GILD AMGN REGN VRTX BIIB

| Held by: VTI VOO SPY IVV VTV SCHD XLV VIG VYM VHT

Scroll to Statements

Index	S&P 500	P/E	61.23	EPS (ttm)	2.87	Insider Own	0.08%	Shs Outstand	1.77B	Perf Week	1.27%
Market Cap	317.62B	Forward P/E	14.39	EPS next Y	12.20	Insider Trans	-19.53%	Shs Float	1.77B	Perf Month	4.66%
Income	5.08B	PEG	7.29	EPS next Q	2.98	Inst Own	72.95%	Short Float	1.09%	Perf Quarter	-9.42%
Sales	55.53B	P/S	5.72	EPS this Y	-1.53%	Inst Trans	-0.08%	Short Ratio	3.16	Perf Half Y	1.64%
Book/sh	3.41	P/B	51.44	EPS next Y	11.53%	ROA	3.63%	Short Interest	19.32M	Perf Year	15.75%
Cash/sh	4.03	P/C	43.60	EPS next 5Y	8.40%	ROE	56.06%	52W Range	151.29 - 207.32	Perf YTD	13.30%
Dividend Est.	6.17 (3.51%)	P/FCF	20.38	EPS past 5Y	-5.77%	ROI	7.87%	52W High	-15.31%	Beta	0.58
Dividend TTM	6.20 (3.53%)	Quick Ratio	0.54	Sales past 5Y	11.76%	Gross Margin	69.87%	52W Low	16.06%	ATR (14)	4.01
Dividend Ex-Date	Jan 15, 2025	Current Ratio	0.65	EPS Y/Y TTM	-21.61%	Oper. Margin	30.61%	RSI (14)	46.96	Volatility	2.63% 2.13%
Employees	50000	Debt/Eq	11.78	Sales Y/Y TTM	0.72%	Profit Margin	9.15%	Recom	1.81	Target Price	204.08
Option/Short	Yes / Yes	LT Debt/Eq	9.70	EPS Q/Q	-12.27%	Payout	220.33%	Rel Volume	2.89	Prev Close	171.52
Sales Surprise	1.24%	EPS Surprise	2.74%	Sales Q/Q	3.83%	Earnings	Oct 30 BMO	Avg Volume	6.12M	Price	175.58
SMA20	-0.62%	SMA50	-3.93%	SMA200	-1.82%	Trades		Volume	17,695,727	Change	2.37%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-24	Resumed	BofA Securities	Neutral	$191
Dec-05-24	Downgrade	Daiwa Securities	Outperform → Neutral	$180
Nov-22-24	Upgrade	Leerink Partners	Market Perform → Outperform	$206
Nov-15-24	Initiated	Wolfe Research	Outperform	$205
Nov-04-24	Upgrade	Argus	Hold → Buy
Oct-17-24	Initiated	Bernstein	Mkt Perform	$203
Jun-05-24	Upgrade	HSBC Securities	Hold → Buy	$185
May-17-24	Initiated	Cantor Fitzgerald	Overweight	$200
Jan-29-24	Upgrade	William Blair	Mkt Perform → Outperform
Dec-18-23	Downgrade	HSBC Securities	Buy → Hold
Dec-11-23	Upgrade	Goldman	Neutral → Buy
Nov-09-23	Initiated	Deutsche Bank	Hold	$150
Oct-30-23	Upgrade	Barclays	Equal Weight → Overweight	$160 → $170
Oct-20-23	Resumed	UBS	Neutral	$157 → $150
Sep-29-23	Initiated	Raymond James	Outperform	$177
Jul-25-23	Initiated	William Blair	Mkt Perform
Jul-14-23	Initiated	HSBC Securities	Buy	$167
Apr-05-23	Downgrade	Argus	Buy → Hold
Mar-01-23	Initiated	Guggenheim	Buy	$172
Feb-22-23	Downgrade	Wolfe Research	Outperform → Peer Perform

Show Previous Ratings

Today 06:48AM	3 Fantastic Stocks That Could Enjoy a Santa Claus Rally (Motley Fool)
Dec-19-24 08:00AM	AbbVie's atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline (PR Newswire)
06:00AM	2 Top Dividend Stocks to Buy and Hold Through 2025 and Beyond (Motley Fool)
04:40AM	Is AbbVie Inc. (ABBV) the Safest Dividend Stock to Invest In Now? (Insider Monkey)
Dec-18-24 09:00AM	Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know (Zacks)
08:49AM	Loading…
08:49AM	AbbVies tavapadon achieves positive topline results in Phase III TEMPO-2 trial (Clinical Trials Arena)
Dec-17-24 08:00AM	AbbVie Takes On Pfizer And Merck With Its Next Leg Of Growth. Will AbbVie Stock Come Back? (Investor's Business Daily)
Dec-16-24 05:45PM	AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors (Zacks)
04:02AM	AbbVie to acquire Nimble Therapeutics for $200m (Pharmaceutical Technology)
03:00AM	3 closely watched drugs that failed in the clinic (Pharma Voice)
Dec-15-24 05:35AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Dec-13-24 02:00PM	This Drugmaker's (ABBV) Parkinson's Medication Just Cleared A Key Hurdle Is It Primed For A Monster Year In 2025? (Benzinga)
09:15AM	AbbVie to Acquire Nimble Therapeutics, Further Strengthening Immunology Pipeline (PR Newswire)
06:00AM	AbbVie to acquire Roche spinout Nimble in immune drug deal (BioPharma Dive)
Dec-12-24 07:41AM	Why AbbVie Inc. (ABBV) Is the Best Safe Stock to Buy According to Analysts? (Insider Monkey)
06:00AM	Loading…
06:00AM	1 Magnificent S&P 500 Dividend Stock Down 14% to Buy and Hold Forever (Motley Fool)
Dec-11-24 09:15AM	AbbVie Completes Acquisition of Aliada Therapeutics (PR Newswire)
05:45AM	BenevolentAI restructures; Lilly preps $15B buyback program (BioPharma Dive)
Dec-10-24 11:17PM	Why Is AbbVie Inc. (ABBV) Among the Best Cosmetic Surgery and Aesthetics Stocks to Invest In Now? (Insider Monkey)
12:08PM	Hope for Parkinsons disease symptoms is found in late-stage drug study (Fortune)
06:00AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
05:20AM	AbbVies Phase III trial of Parkinsons disease treatment meets primary endpoint (Clinical Trials Arena)
Dec-09-24 12:00PM	Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (PR Newswire)
11:16AM	AbbVie's Early Parkinson's Candidate Hits Primary Goal In Pivotal Late-Stage Study (Benzinga)
08:00AM	AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson's Disease (PR Newswire)
03:00AM	Endometriosis drug research, long underfunded, confronts familiar problems in womens health (BioPharma Dive)
Dec-08-24 03:00PM	AbbVie Announces Emotional Impact Report on Mental Health of Underrepresented CLL Cancer Patients (PR Newswire)
Dec-07-24 07:00PM	Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Shows High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) (PR Newswire)
Dec-05-24 09:00AM	How To Put $100 In Your Retirement Fund Each Month With AbbVie Stock (Benzinga)
Dec-04-24 08:21AM	Why Is AbbVie Inc. (ABBV) Among the Dividend Kings You Should Consider? (Insider Monkey)
12:18PM	Loading…
Dec-03-24 12:18PM	From Cobenfy to Emraclidine: the muscarinic path to safer antipsychotics (Pharmaceutical Technology)
09:00AM	Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock (Zacks)
04:24AM	3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer (Motley Fool)
Dec-02-24 02:52PM	Why Dividend Aristocrats Like Walmart, ADP, and AbbVie Are Set to Outperform (Barrons.com)
07:50AM	Analyst Report: AbbVie Inc. (Morningstar Research)
07:00AM	Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024 (Business Wire)
Dec-01-24 05:52AM	3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later (Motley Fool)
Nov-30-24 04:19PM	Why AbbVie Inc. (ABBV) Is One of the Most Profitable Pharmaceutical Stocks Right Now? (Insider Monkey)
05:41AM	Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever (Motley Fool)
Nov-29-24 11:36AM	Galderma Bets on Skin Drug to Turn Around Pharma Business (The Wall Street Journal)
11:31AM	Why Is AbbVie (ABBV) Down 10.2% Since Last Earnings Report? (Zacks)
Nov-28-24 05:35AM	Why AbbVie Inc. (ABBV) Is One of the Most Undervalued Pot Stocks to Buy? (Insider Monkey)
Nov-26-24 06:00AM	Navigating Market Uncertainty: Intrinsic Value of AbbVie Inc (GuruFocus.com)
05:03AM	2 High-Yield Dividend Stocks to Buy Now for a Lifetime of Passive Income (Motley Fool)
01:00AM	Is AbbVie Inc. (ABBV) the Best Dividend Aristocrat Stock To Buy Right Now? (Insider Monkey)
Nov-25-24 08:00AM	AbbVie to Present at Citi's 2024 Global Healthcare Conference (PR Newswire)
Nov-23-24 10:19AM	Are Hedge Funds Betting Big On AbbVie Inc. (ABBV)? (Insider Monkey)
09:17AM	The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys (Motley Fool)
07:20AM	3 Dividend Stocks That Are Screaming Buys in November (Motley Fool)
06:20AM	AbbVie upgraded to Outperform from Market Perform at Leerink (TipRanks)
Nov-22-24 04:23PM	AbbVie gains on Leerink Partners upgrade to Outperform (Yahoo Finance Video)
04:09PM	AbbVie Jumps 5% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
02:10PM	Trade Tracker: Jim Lebenthal buys more Abbvie (CNBC TV)
12:25PM	J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis (Pharmaceutical Technology)
11:30AM	AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback (Investor's Business Daily)
Nov-20-24 09:00AM	Is Trending Stock AbbVie Inc. (ABBV) a Buy Now? (Zacks)
Nov-19-24 10:00AM	Where Will AbbVie Be in 5 Years? (Motley Fool)
03:00AM	What is a cure, really? AbbVies Humira creator leaps into the next phase of medicine (Pharma Voice)
Nov-18-24 09:00AM	Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products (PR Newswire)
07:07AM	AbbVies Elahere wins European approval for certain ovarian cancers (Pharmaceutical Technology)
07:00AM	Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip (Motley Fool)
01:00AM	AbbVie Receives European Commission Approval of ELAHERE (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer (PR Newswire)
12:47AM	Analyst Report: AbbVie Inc. (Morningstar Research)
Nov-16-24 10:08AM	Why AbbVies (ABBV) Drug Setback Creates A Prime Buy-The-Dip Moment (Insider Monkey)
Nov-15-24 05:50AM	Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock (Motley Fool)
Nov-14-24 05:56PM	Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV (GuruFocus.com)
02:01PM	Final Trades: Bitcoin, Abbvie and Baker Hughes (CNBC TV)
10:15AM	2 Dividend Stocks to Buy Hand Over Fist in November (Motley Fool)
08:15AM	AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations (PR Newswire)
Nov-12-24 01:52PM	AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio (Benzinga)
08:12AM	AbbVies stock plummets over 12% after schizophrenia drug flops in Phase II trials (Clinical Trials Arena)
07:00AM	What the NFL Draft Can Teach Investors About Big Pharma (The Wall Street Journal)
06:00AM	Beyond Market Price: Uncovering AbbVie Inc's Intrinsic Value (GuruFocus.com)
Nov-11-24 06:34PM	Analyst Report: AbbVie Inc. (Morningstar Research) -12.57%
04:32PM	S&P 500 Gains and Losses Today: Index Closes Above 6,000 on Post-Election Rally (Investopedia)
04:04PM	Bristol Rockets 11% As Investors Question AbbVie's $8.7 Billion 'Mistake' (Investor's Business Daily)
03:45PM	AbbVie tumbles on drug test disappointment, Bristol-Myers gains (Yahoo Finance Video)
03:22PM	Why AbbVie Stock Was Getting Mashed on Monday (Motley Fool)
01:20PM	Trade Tracker: Jim Lebenthal buys more Abbvie (CNBC TV)
12:51PM	AbbVie's Emraclidine For Schizophrenia 'Surprisingly Disappoints,' Analyst Says Pipeline Is Underappreciated (Benzinga)
12:18PM	AbbVie Stock Sinks After Schizophrenia Drug Trials Disappoint (Investopedia)
12:04PM	Top Stock Movers Now: Tesla, Robinhood Markets, MicroStrategy, and More (Investopedia)
11:16AM	AbbVie Tumbles After New Schizophrenia Drug Fails Two Trials (Bloomberg)
10:47AM	AbbVie Stock Tumbles on Failed Schizophrenia Drug Studies. Bristol Myers Jumps. (Barrons.com)
10:12AM	Bristol Myers Rockets 12% After AbbVie's Schizophrenia Drug Fails (Investor's Business Daily)
10:08AM	AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS (FierceBiotech.com)
09:39AM	AbbVie Stock Slides on Schizophrenia Drug Study Failure (The Wall Street Journal)
09:17AM	AbbVie shares slip after schizophrenia drug trial misses primary endpoint (Investing.com)
08:30AM	AbbVie Provides Update on Phase 2 Results for Emraclidine in Schizophrenia (PR Newswire)
Nov-10-24 01:28PM	Dividend Investor Who Started 'Homeless and Penniless' Now Earns $4,800 a Month, Reveals Top 5 Stock Holdings (Benzinga)
09:30AM	3 Spectacular High-Yield Dividend Stocks to Buy in November (Motley Fool)
Nov-09-24 05:48AM	My Favorite Dividend King to Buy in November (Motley Fool)
Nov-08-24 09:38AM	Analyst Report: AbbVie Inc. (Morningstar Research)
09:30AM	Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy? (Zacks)
05:00AM	2 Dividend Kings That Would Have Doubled Your Money in 5 Years (Motley Fool)
Nov-07-24 08:00AM	Allergan Aesthetics Celebrates Annual BOTOX Cosmetic (onabotulinumtoxinA) Day (PR Newswire)
Nov-06-24 12:26PM	Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology)
Nov-05-24 09:00AM	Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now? (Zacks)
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
12:06AM	Decoding AbbVie Inc (ABBV): A Strategic SWOT Insight (GuruFocus.com)

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Option Exercise	93.50	1,800	168,300	8,783	Dec 18 05:00 PM
Buckbee Kevin K	SVP, CONTROLLER	Dec 16 '24	Sale	172.24	1,800	310,032	6,983	Dec 18 05:00 PM
Buckbee Kevin K	Officer	Dec 16 '24	Proposed Sale	172.25	1,800	310,045		Dec 16 05:34 PM
Hudson Thomas J	Officer	Aug 08 '24	Proposed Sale	189.08	49,170	9,297,210		Aug 08 05:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Aug 05 '24	Sale	186.52	66,500	12,403,580	446,599	Aug 07 05:00 PM
Hudson Thomas J	Officer	Aug 07 '24	Proposed Sale	187.62	101,886	19,115,380		Aug 07 04:22 PM
GONZALEZ RICHARD A	Officer	Aug 05 '24	Proposed Sale	187.36	66,500	12,459,360		Aug 05 10:54 AM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Option Exercise	77.49	282,845	21,919,048	795,944	Jul 19 04:40 PM
GONZALEZ RICHARD A	EXECUTIVE CHAIRMAN OF BOARD	Jul 17 '24	Sale	175.00	282,845	49,497,875	513,099	Jul 19 04:40 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Mar 20 '24	Sale	176.30	21,082	3,716,757	55,903	Mar 22 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Option Exercise	61.36	26,110	1,602,110	119,890	Mar 20 05:00 PM
Stewart Jeffrey Ryan	EVP, CHIEF COMMERCIAL OFFICER	Mar 18 '24	Sale	178.79	58,949	10,539,508	60,941	Mar 20 05:00 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Option Exercise	61.36	45,700	2,804,152	89,517	Mar 05 05:30 PM
RICHMOND TIMOTHY J.	EVP, CHIEF HR OFFICER	Mar 01 '24	Sale	177.27	75,680	13,415,503	13,837	Mar 05 05:30 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Option Exercise	61.36	14,140	867,630	41,205	Mar 01 05:50 PM
Reents Scott T	EVP, CHIEF FINANCIAL OFFICER	Feb 23 '24	Sale	177.44	14,140	2,509,002	27,065	Mar 01 05:50 PM
Buckbee Kevin K	SVP, CONTROLLER	Feb 29 '24	Sale	176.65	5,144	908,688	6,983	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Option Exercise	58.30	21,560	1,257,012	167,524	Mar 01 05:50 PM
Michael Robert A.	PRES & CHIEF OPERATING OFFICER	Feb 29 '24	Sale	176.45	68,879	12,153,957	98,645	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 29 '24	Sale	177.39	9,891	1,754,555	10,397	Mar 01 05:50 PM
GONZALEZ RICHARD A	CHAIRMAN OF THE BOARD AND CEO	Feb 28 '24	Sale	177.27	138,616	24,572,458	519,099	Mar 01 05:50 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Option Exercise	137.36	13,753	1,889,115	41,926	Feb 27 05:10 PM
Siatis Perry C	EVP, GC AND SECRETARY	Feb 23 '24	Sale	177.51	13,753	2,441,295	28,173	Feb 27 05:10 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Option Exercise	58.88	52,870	3,112,986	296,814	Feb 23 05:00 PM
SALEKI-GERHARDT AZITA	EVP, CHIEF OPERATIONS OFFICER	Feb 21 '24	Sale	173.71	52,870	9,184,048	243,944	Feb 23 05:00 PM
Donoghoe Nicholas	EVP, CHIEF BUS/STRAT OFFICER	Dec 26 '23	Sale	154.72	2,912	450,545	55,903	Dec 28 05:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ABBV

Abbvie Inc

Upgrade your FINVIZ experience